The Court Order was issued June 22. Trading in Centessa ADSs halts June 24. By the time most site coordinators read their morning emails, Eli Lilly will legally own the orexin OX2R agonist program they have been running — and the operational clock on a dozen parallel processes will already be ticking. The $7.8 billion acquisition of Centessa Pharmaceuticals by Eli Lilly and Company, approved by the High Court of Justice of England and Wales and structured as a Court-sanctioned scheme of arrangement under English law, is a corporate event with a clean legal close date. The operational reality at active trial sites is considerably messier.
Sites running Centessa’s CRYSTAL-1 program — the Phase 2a study evaluating cleminorexton (ORX750), the lead orexin receptor 2 agonist, in narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia — are now operating in the window that every experienced CRC dreads: the gap between corporate close and operational handoff. Centessa had planned to initiate a registrational program for cleminorexton in Q1 2026, which means some sites are potentially mid-activation or early enrollment when the ownership transfer occurs. That timing creates compounding pressure that does not show up in any press release.
The IND Transfer Is the Starting Gun
Here is what the legal announcement does not say: under 21 CFR Part 312, Subpart D, IND sponsorship transfers require a written agreement between the transferring sponsor and the new sponsor, followed by notification to FDA. Until that transfer is formally executed and acknowledged, the regulatory obligations — SAE reporting timelines, IND safety report submissions, protocol amendment authority — remain with the entity named on the IND. In an acquisition that closes on a Tuesday, the legal entity owning the asset and the entity of record on the IND can be two different organizations for a period of days to weeks. Sites caught in that window face a disorienting question: who do you call when a serious adverse event drops at 11 PM?
The answer, on paper, is whoever holds the IND. In practice, the Centessa clinical operations team may be mid-integration, the CRO contact list may already be in flux, and the 24-hour safety line number in the protocol may route to a team that no longer exists in its original form. Sites I work with across multiple therapeutic areas have navigated this exact confusion after large-cap acquisitions, and the common thread is always the same: the site had no updated emergency contact protocol in hand at the moment of close, because the acquiring company’s communications team was focused on investors, not coordinators.
That gap has direct regulatory consequences. ICH E6(R3), Section 5.5, places explicit responsibility on the sponsor to communicate all relevant trial information to investigators in a timely manner. When the sponsor entity changes, so does the communication chain — and sites are entitled to written confirmation of that chain before the next monitoring visit, not after. Coordinators who do not receive updated sponsor contact documentation within 72 hours of an acquisition close should escalate in writing to their CRA and document the request in the site file. That paper trail matters if an FDA BIMO inspection ever asks about the continuity of sponsor oversight during the transition period.
The Platform Migration Nobody Budgets For
Lilly operates at a scale that Centessa, as a clinical-stage company, did not. That means the EDC system, the IRT platform, the eTMF solution, and the safety reporting portal that sites learned during Centessa’s SIVs are almost certainly not the systems that will carry the program through Phase 3. The registrational program for cleminorexton, which was targeted to begin in early 2026, will now be built inside Lilly’s enterprise infrastructure — and the migration from Centessa’s existing eClinical stack to Lilly’s preferred vendors is a retraining event that falls squarely on site staff who are already managing active data entry and monitoring obligations.
Platform migrations mid-trial are among the most underestimated sources of data query accumulation and deviation risk in the industry. A coordinator who has been entering assessments in one EDC interface for six months and is then handed credentials to a new system with a four-hour training module and a go-live date tied to a corporate integration milestone will make entry errors. Not because she is careless — because the validated fields, the navigation logic, and the save confirmation screens are all different, and she is doing it while managing seven other protocols. In our network, query aging spikes measurably in the 90-day window following an EDC migration, and that spike creates monitoring visit findings that sites then spend additional hours resolving.
The cost arithmetic is straightforward and almost never appears in a sponsor’s integration budget. Assume a site coordinator spends 12 additional hours in retraining, query resolution, and re-entry support during a platform migration. At a fully loaded coordinator cost of $45 to $65 per hour, that is $540 to $780 per site per system that migrates — before accounting for PI time reviewing re-consented documents if the ICF version changes as part of the new sponsor’s standard language. Multiply across 20 or 30 active sites in an early-phase neurology program and the number becomes operationally significant, yet it appears nowhere in the acquisition term sheet or the CVR milestone structure.
Contract Amendments Are Not Administrative Events
The $7.8 billion deal value includes $38.00 per share in cash plus a contingent value right worth up to $9.00 per share, tied to three undisclosed milestones. From a site perspective, those milestones are irrelevant — what matters is that the acquiring company will renegotiate or amend every active site contract and budget to reflect its own payment infrastructure, its own standard fee schedule, and its own compliance requirements. Lilly’s vendor and site payment systems operate on Lilly terms, not Centessa terms.
Sites should review their current fully executed clinical trial agreements before the new sponsor issues amendment paperwork. Specifically, look at the governing law clause, the indemnification structure, and any provisions that reference Centessa by name as a party. A scheme of arrangement under English law transfers the corporate entity, but site agreements drafted under Delaware law with Centessa Pharmaceuticals plc as the named sponsor may require explicit novation rather than simple assignment — and the distinction matters if a dispute arises about a payment that was earned under the old contract structure but processed under the new one. Raise this with your institution’s legal or contracts office now, not when the amendment lands in your inbox.
The IRB side carries its own timing pressure. If the new sponsor’s standard language for the informed consent form differs materially from Centessa’s existing approved version — different sponsor contact information, different liability language, different CVR-related disclosure requirements — sites face an IRB amendment submission that will consume four to six weeks under most central IRB review cycles. Subjects enrolled under the existing ICF version remain under that version until the amendment is approved and implemented, which means coordinators must maintain two parallel consent tracking workflows during the transition. That is not a hypothetical; it is a routine consequence of mid-trial sponsor changes that enrollment planning timelines almost never account for.
For site operations leads and sponsors managing the integration on the Lilly side, the most concrete action available right now is a pre-amendment site readiness communication: a single document that confirms the SAE reporting pathway, the CRA assignment continuity (or the date on which it will change), the EDC access status, and the timeline for contract amendment issuance. Send it before June 30. Sites that receive it will manage the transition with far less disruption than sites that are still waiting for clarity when their next monitoring visit is due. The operational reality of a $7.8 billion deal is that it closes in a courtroom in London — but it lands on a coordinator’s desk in Cleveland, and how it lands there determines whether the program hits its next milestone on time.
The cleminorexton registrational program represents a genuine scientific bet on orexin biology in narcolepsy and hypersomnia — and whether that bet pays off will depend not on the deal structure, but on whether the sites carrying the data can absorb this transition without losing enrollment momentum or accumulating the kind of deviation record that complicates an NDA submission.
References
- Centessa Pharmaceuticals — “Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales,” GlobeNewswire, June 22, 2026
- MarketBeat — “Centessa Pharmaceuticals CEO Teases ‘Transformational 2026’ as ORX750 Nears Registrational Trials,” February 2026
- AcquisitionStars — “Life Sciences Pharmaceutical M&A Legal Guide: 21 CFR Part 312 IND Transfer Requirements”
